Compare Eli Lilly And Co (LLY) vs Health Care Select Sector SPDR Fund (XLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Health Care Select Sector SPDR Fund — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while Health Care Select Sector SPDR Fund trades at $170.81 (market cap $43.48B). The key difference: Eli Lilly And Co is far larger — about 23.9× Health Care Select Sector SPDR Fund's market cap, and Eli Lilly And Co pays a 0.59% dividend while Health Care Select Sector SPDR Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Health Care Select Sector SPDR Fund for 100 Days on average.
| LLY | XLV | |
|---|---|---|
Market Cap | $1.04T | $43.48B |
Volume | 3,064,878 | 11,121,431 |
Sector | Health | — |
52-Week High | $1.28K | $175.68 |
52-Week Low | $799.57 | $141.95 |
Typical Hold Time | 93 Days | 100 Days |
Enterprise Value | $1.09T | — |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company demonstrates exceptional profitability with 83.4% gross margins and 33.53% net income margins, supported by dominant positioning in weight-loss and diabetes treatments. Recent clinical trial successes for next-generation drugs and expanded FDA approvals reinforce growth prospects.
LLY presents compelling growth potential with analyst consensus target of $1,350 representing 15% upside, though elevated valuations (P/E 39.26) and increasing competition in obesity drugs pose risks. Strong institutional support (73% buy ratings) and positive pipeline developments support continued momentum, but investors should monitor execution risks and market saturation concerns.
XLV trades at $168.16, down 0.39% with a bearish technical signal from moving averages. The healthcare ETF maintains strong cost advantages with a 0.08% expense ratio compared to peers. Recent news highlights XLV's defensive positioning during market volatility and its historical outperformance during Fed rate hikes. Technical indicators show RSI levels in neutral territory while ADX signals selling pressure.
XLV offers diversified healthcare exposure with competitive expense ratios, positioning it well for defensive investing. Key risks include political uncertainty around healthcare policy and concentrated exposure to domestic S&P 500 stocks. The ETF's low-cost structure and sector diversification provide stability amid market volatility, though technical indicators suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Health Care Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →
